BACKGROUND: Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). The neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, is associated with outcome in several cancer types. AIMS: To study the association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival (PFS) and overall survival (OS) of patients treated with sunitinib for mRCC. METHODS: We retrospectively studied an unselected cohort of patients with mRCC, who were treated with sunitinib. Logistic regression model was used to analyse response rate. Cox regression models were fitted to identify risk factors associated with PFS and OS. We investigated how pre-treatment NLR is associated with these clinical outcomes after adjusting for confounding covariates. Regression tree for censored data method was used to find the best NLR cut-off value. RESULTS: Between 2004 and 2011, 133 patients with mRCC were treated with sunitinib. One hundred and nine were included in the NLR analysis, from which were excluded patients without available data on pre-treatment NLR or with comorbidities/recent treatments known to be associated with a change of blood counts. Factors associated with PFS were low NLR ≤ 3 (HR = 0.285, p < 0.001), past nephrectomy (HR = 0.38, p = 0.035), sunitinib dose reduction/treatment interruption (HR = 0.6, p = 0.014) and the use of antiotensin system inhibitors (HR = 0.537, p = 0.008). Low NLR ≤ 3 was associated with OS (HR = 0.3, p = 0.043). CONCLUSIONS: In patients with mRCC treated with sunitinib, pre-treatment NLR may be associated with PFS and OS. This should be investigated prospectively, and if validated applied in clinical practice and clinical trials.
BACKGROUND:Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). The neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, is associated with outcome in several cancer types. AIMS: To study the association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival (PFS) and overall survival (OS) of patients treated with sunitinib for mRCC. METHODS: We retrospectively studied an unselected cohort of patients with mRCC, who were treated with sunitinib. Logistic regression model was used to analyse response rate. Cox regression models were fitted to identify risk factors associated with PFS and OS. We investigated how pre-treatment NLR is associated with these clinical outcomes after adjusting for confounding covariates. Regression tree for censored data method was used to find the best NLR cut-off value. RESULTS: Between 2004 and 2011, 133 patients with mRCC were treated with sunitinib. One hundred and nine were included in the NLR analysis, from which were excluded patients without available data on pre-treatment NLR or with comorbidities/recent treatments known to be associated with a change of blood counts. Factors associated with PFS were low NLR ≤ 3 (HR = 0.285, p < 0.001), past nephrectomy (HR = 0.38, p = 0.035), sunitinib dose reduction/treatment interruption (HR = 0.6, p = 0.014) and the use of antiotensin system inhibitors (HR = 0.537, p = 0.008). Low NLR ≤ 3 was associated with OS (HR = 0.3, p = 0.043). CONCLUSIONS: In patients with mRCC treated with sunitinib, pre-treatment NLR may be associated with PFS and OS. This should be investigated prospectively, and if validated applied in clinical practice and clinical trials.
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Daniel Keizman; Peng Huang; Mario A Eisenberger; Roberto Pili; Jenny J Kim; Emmanuel S Antonarakis; Hans Hammers; Michael A Carducci Journal: Eur J Cancer Date: 2011-05-18 Impact factor: 9.162
Authors: S Patil; R A Figlin; T E Hutson; M D Michaelson; S Négrier; S T Kim; X Huang; R J Motzer Journal: Ann Oncol Date: 2010-07-25 Impact factor: 32.976
Authors: Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke Journal: Clin Cancer Res Date: 2010-10-18 Impact factor: 12.531
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Sahin Ulu; Abdulkadir Bucak; M Sena Ulu; Ahmet Ahsen; Abidin Duran; Fatih Yucedag; Abdullah Aycicek Journal: Eur Arch Otorhinolaryngol Date: 2014-10 Impact factor: 2.503
Authors: Mudit Chowdhary; Jeffrey M Switchenko; Robert H Press; Jaymin Jhaveri; Zachary S Buchwald; Philip A Blumenfeld; Gaurav Marwaha; Aidnag Diaz; Dian Wang; Ross A Abrams; Jeffrey J Olson; Hui-Kuo G Shu; Walter J Curran; Kirtesh R Patel Journal: J Neurooncol Date: 2018-05-30 Impact factor: 4.130
Authors: Angelina Tjokrowidjaja; David Goldstein; H Malcolm Hudson; Sarah J Lord; Val Gebski; Stephen Clarke; Paul de Souza; Robert J Motzer; Chee Khoon Lee Journal: Acta Oncol Date: 2019-08-29 Impact factor: 4.089
Authors: Philipp Nuhn; Ajay M Vaghasia; Jatinder Goyal; Xian C Zhou; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis Journal: BJU Int Date: 2014-02-14 Impact factor: 5.588
Authors: Ahmet Taner Sümbül; Ahmet Sezer; Hüseyin Abalı; Fatih Köse; Ilhami Gültepe; Hüseyin Mertsoylu; Sadık Muallaoğlu; Özgür Özyılkan Journal: Int Urol Nephrol Date: 2014-02-13 Impact factor: 2.370